real-time news and commentary for investors
Sunday, Sep 1
Amgen's AMG 145 shown to reduce bad cholesterol
- Amgen (AMGN) says patients treated with the investigational PCSK9 inhibitor AMG 145 exhibited reductions in bad cholesterol of up to 59%.
- The efficacy analysis data showed mean LDL-C reductions of between 40-59% from baseline to week 12.
- PCSK9 targets LDL receptors and impairs the liver's ability to remove bad cholesterol from the blood.
- AMGN is currently conducting a large Phase 3 trial. (PR)